Characterization of the antibody responses elicited upon SARS-CoV-2 infection

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U19AI111825-07S1

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



AbstractExtensive research on the basic immunological mechanisms that drive human immunity has provided the generalframework by which the human immune system responds to foreign antigens. However, it is well-appreciatedthat each viral infection poses unique challenges to the immune system and the elicited immune responses arecharacterized by substantial heterogeneity that impacts disease susceptibility and pathogenesis, by conferringeither protective or disease-enhancing activities. The ongoing COVID-19 pandemic represents a significantthreat for global public health with tremendous socio-economic consequences. Early clinical and epidemiologicaldata from COVID-19 patients suggest that while for the majority of the population, SARS-CoV-2 infection causesmild symptoms that usually resolve within a few weeks, a substantial fraction of patients develops severe, oftenlife-threatening, clinical complications, including acute respiratory distress syndrome and pneumonia.Differences in the induction of protective antiviral immunity likely accounts for the differential susceptibility tosevere disease upon SARS-CoV-2 infection. Understanding the heterogeneity of immune responses elicitedupon SARS-CoV-2 infection is therefore critical for characterizing the immune mechanisms that confer protectionagainst COVID-19 disease, guiding the development of novel therapeutics for disease control, as well as,determining disease susceptibility in high-risk populations. The proposed studies aim to characterize theantibody responses that are elicited upon infection with SARS-CoV-2, determining the breadth of antibodyspecificities, neutralization potency, as well as Fc domain heterogeneity of anti-SARS-CoV-2 IgG antibodies.More specifically, we plan to recruit recovered COVID-19 patients and systematically analyze their B-cellresponses to determine their transcriptomic profile, as well as the functional properties of their B-cell receptors.In parallel, serologic studies from these individuals aim to characterize the breadth and potency of theirneutralization activity and determine the subclass and Fc glycan distribution of anti-SARS-CoV-2 antibodies.Additionally, Fc domain function will be assessed in well-established ADCC, ADCP, and ADE assays to evaluatethe capacity of anti-SARS-CoV-2 IgG antibodies to confer protective or pathogenic activities. Follow-up serologicstudies will be performed in a large cohort of patients with variable disease severity, ranging from asymptomaticto severe symptomatic cases, to determine the functional activity of elicited anti-SARS-CoV-2 antibodies andassess their Fc domain heterogeneity and effector function. These studies are within the scope of our parentgrant, as they are focused on the understanding of the immune responses that are elicited during viral infection.We anticipate that the findings of these studies will provide novel insights into the immunological mechanismsthat confer protection or susceptibility to COVID-19 disease, accelerating our efforts for the development ofvaccine or therapeutic interventions for the control of SARS-CoV-2 infection.